Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs

Molecular Cancer Therapeutics

Volumn 4, Issue 4, 2005, Pages 659-667

  Landowski, Christopher P ^a   Vig, Balvinder S ^a,b   Song, Xueqin ^a   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' ASPARTYL FLOXURIDINE; 3' LYSYL FLOXURIDINE; 3',5' ASPARTYL FLOXURIDINE; 3',5' LYSYL FLOXURIDINE; 5' ASPARTYL FLOXURIDINE; 5' LYSYL FLOXURIDINE; ANTINEOPLASTIC AGENT; FLOXURIDINE DERIVATIVE; PEPTIDE TRANSPORTER 1; PRODRUG; UNCLASSIFIED DRUG; VALACICLOVIR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL FREE SYSTEM; CELL PROLIFERATION; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG DESIGN; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; FEASIBILITY STUDY; HELA CELL; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACIDS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CACO-2 CELLS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FLOXURIDINE; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INHIBITORY CONCENTRATION 50; LYSINE; MODELS, CHEMICAL; NEOPLASM METASTASIS; NUCLEOSIDES; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; PRODRUGS; PROLINE; SYMPORTERS; TIME FACTORS;

EID: 18044374166     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0290     Document Type: Article

References (34)

1. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000;18:299-313.
2. Nishizawa Y, Casida JE. 3′,5′-Diesters of 5-fluoro-2′-deoxyuridine: synthesis and biological activity. Biochem Pharmacol 1965;14:1605-19.
3. Kawaguchi T, Saito M, Suzuki Y, Nambu N, Nagai T. Specificity of esterases and structure of prodrug esters. II. Hydrolytic regeneration behavior of 5-fluoro-2′ deoxyuridine (FUdR) from 3′,5′-diesters of FUdR with rat tissue homogenates and plasma in relation to their antitumor activity. Chem Pharm Bull (Tokyo) 1985;33:1652-9.
4. Tobias SC, Borch RF. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. J Med Chem 2001;44:4475-80.
5. Wei Y, Yan Y, Pei D, Gong B. A photoactivated prodrug. Bioorg Med Chem Lett 1998;8:2419-22.
6. Vig BS, Lorenzi PJ, Mittal S, et al. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res 2003;20:1381-8.
7. Shin HC, Landowski CP, Amidon GL. Transporters in the GI Tract. In: Van de Waterbeemd H, Lennernas H, Artursson P, editors. Drug bioavailability/estimation of solubility, permeability and absorption (Series: Methods and principles in medicinal chemistry). Weinheim (Germany): Wiley-VCH Verlag GmbH; 2003. p. 245-87.
8. Han H, de Vrueh RL, Rhie JK, et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 1998a;15:1154-9.
9. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000;89:781-9.
10. Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 1998;246:470-5.
11. Gonzalez DE, Covitz KM, Sadee W, Mrsny RJ. An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res 1998;58:519-25.
12. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002;62:819-26.
13. Nakanishi T, Tamai I, Sai Y, Sasaki T, Tsuji A. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res 1997;57:4118-22.
14. Nakanishi T, Tamai I, Takaki A, Tsuji A. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer 2000;88:274-80.
15. Casida JE, Engel JL, Nishizawa Y. 3′,5′-Diesters of 5-fluoro-2′-deoxyuridine and thymidine: hydrolysis by esterases in human, mouse, and insect tissue. Biochem Pharmacol 1966;15:627-44.
16. Williams FM. Clinical significance of esterases in man. Clin Pharmacokinet 1985;10:392-403.
17. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: from molecular structure to function. Drug Metab Dispos 2002;30:488-93.
18. Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, Amidon GL. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem 2003;278:25348-56.
19. Kim I, Song X, Vig BS, et al. A novel nucleoside prodrug activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm 2004;1:117-27.
20. Landowski CP, Sun D, Foster DR, et al. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther 2003;306:778-86.
21. Hsu CP, Hilfinger JM, Walter E, Merkle HP, Roessler BJ, Amidon GL. Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res 1998;15:1376-81.
22. Han HK, Oh DM, Amidon GL. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res 1998b;15:1382-6.
23. Bruice TC, Benkovic S. Bioorganic mechanisms. New York: W.A. Benjamin, Inc.; 1966.
24. Kawaguchi T, Fukushima S, Hayashi Y, Nakano M. Nonenzymatic and enzymatic hydrolysis of 5-fluoro-2′-deoxyuridine (FUdR) esters. Pharm Res 1988;5:741-4.
25. Beauchamp LM, Orr GF, de Miranda P, Burnette T, Kernitsy TA. Amino acid ester prodrugs of acyclovir. Antivir Chem Chemother 1992;3:157-64.
26. Sinko PJ, Balimane PV. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir. 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos 1998;19:209-17.
27. Wahl ML, Owen JA, Burd R, et al. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 2002;1:617-28.
28. + diffusion to the acidic pH of tumors. Neoplasia 2003; 5:135-45.
29. Friedrichsen GM, Chen W, Begtrup M, Lee CP, Smith PL, Borchardt RT. Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells. Eur J Pharm Sci 2002;16:1-13.
30. Amidon GL, Chang M, Fleisher D, Allen R. Intestinal absorption of amino acid derivatives: importance of the free α-amino group. J Pharm Sci 1982;71:1138-41.
31. Yang C, Gao H, Mitra AK. Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir. J Pharm Sci 2001;90:617-24.
32. Glenner GG, McMillan PJ, Folk JE. A mammalian peptidase specific for the hydrolysis of N-terminal α-L-glutamyl and aspartyl residues. Nature 1962;194:867.
33. Zhan CG, Zheng F, Landry DW. Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J Am Chem Soc 2003; 125:2462-74.
34. Faria TN, Timoszyk JK, Stouch TR, et al. A novel high-throughput pept1 transporter assay differentiates between substrates and antagonists. Mol Pharm 2004;1:67-76.